SCHEMBL27382487

SCHEMBL27382487

CC(=O)NCc1cc2cc(C)c(C(C)C)cc2[nH]1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 5/20 0.46
▸ KDM4E B2RXH2 4/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ MTNR1A P48039 8/20 0.43
▸ MTNR1B P49286 7/20 0.43
▸ MAPT P10636 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ RAB9A P51151 2/20 0.39
▸ TSHR P16473 3/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ EIF4A3 P38919 1/20 0.38
▸ HPGD P15428 2/20 0.37
▸ CASP1 P29466 1/20 0.37
▸ CASP7 P55210 1/20 0.37
▸ TP53 P04637 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27382492 0.87 HSD17B10 (0.45) HSD17B10KDM4EALDH1A1CYP1A2MTNR1A
SCHEMBL27382678 0.85 EIF4A3 (0.56) HSD17B10KDM4EALDH1A1CYP1A2MTNR1A
SCHEMBL27383362 0.83 RAB9A (0.38) HSD17B10KDM4EALDH1A1CYP1A2MTNR1A
SCHEMBL27384339 0.82 MAPK1 (0.42) HSD17B10KDM4EALDH1A1CYP1A2MAPT
SCHEMBL27382672 0.81 HSD17B10 (0.48) HSD17B10KDM4EALDH1A1CYP1A2MTNR1A
SCHEMBL27382677 0.78 RAB9A (0.48) HSD17B10KDM4EALDH1A1CYP1A2MTNR1A
SCHEMBL27382556 0.74 EIF4A3 (0.54) KDM4ESMN1; SMN2RAB9ATSHRNPC1
SCHEMBL27384491 0.73 SMN1; SMN2 (0.43) MTNR1AMTNR1BMAPTSMN1; SMN2RAB9A
SCHEMBL27382673 0.73 EIF4A3 (0.53) HSD17B10KDM4EALDH1A1MTNR1AMTNR1B
SCHEMBL27382489 0.71 SMN1; SMN2 (0.47) HSD17B10KDM4EALDH1A1CYP1A2MTNR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024081748-A2 INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF MAZE THERAPEUTICS, INC. (US) 2024-04-18 — — WO disclosed
Send feedback